Agroaceite, a subsidiary of AgroAmerica Tropical Oil Holding Corp. is Awarded the Community Impact RSPO Excellence Award 2019
20.11.2019 19:31:00 EET | Business Wire | Press release
Agroaceite, a subsidiary of AgroAmerica, was awarded the Community Impact RSPO Excellence Award 2019 for the implementation of the "Human Development Center" project (HDC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191120005702/en/
Agroaceite, a subsidiary of AgroAmerica Tropical Oil Holding Corp. was awarded the Community Impact RSPO Excellence Award 2019 for the implementation of the "Human Development Center" project (HDC). The subsidiary has donated 10ha of plantations for the construction of the project that is comprised of a Medical Clinic and school for children of workers in Southwestern Guatemala. "It reflects the company's comprehensive vision to provide access to high-quality education & health coverage," Gustavo Bolaños -AgroAmerica COO- (Photo: Business Wire)
The HDC project is based on the Sustainable Development Goals ; and is executed by Agroaceite, a subsidiary of AgroAmerica Tropical Oil Holding Corp; which has donated 10ha of plantations for the construction of the project that is comprised of a Medical Clinic and school for children of workers:
• Medical Clinic: Conducted in partnership with the University of Colorado to promote integral health access. It opened in 2014 and has impacted more than 27 thousand patients in the Southwestern region of Guatemala. It also runs community programs, in which 3,343 children and 1,977 women have participated, to reduce maternal and infant mortality and improve the nutritional status of the area.
• School for children of workers: Established to raise the academic level of the area, the school has obtained regional recognition for academic performance and pedagogical methodology.
"It reflects the company's comprehensive vision to provide access to high-quality education & health coverage," Gustavo Bolaños -AgroAmerica COO-.
With more than 4,000 members from 92 countries around the world, the RSPO organized, for the first time, the RSPO 2019 Excellence Awards Ceremony to recognize their member’s contributions to sustainable production with practices that go beyond the regulations standards.
The award was presented during the seventeenth Annual RSPO Conference -RT17- held in Bangkok, Thailand. A jury of experts in the palm oil and sustainability sector evaluated RSPO member’s projects in 5 categories: Human Rights and Labour Initiative, Conservation Leadership, Smallholder Impact Programme, Community Impact, and Outstanding Achievement.
About AgroAmerica Tropical Oil Holding Corp.:
It is AgroAmerica’s business unit that engages in the production and marketing of Tropical Oil products.
AgroAmerica is committed to contributing to the well being of people through innovation and technological investment for the development of products, services, programs and projects that promote welfare in the company’s stakeholders.
Visit us: https://agroamerica.com/en/
----------------------------------------------------------------
About Agroaceite:
Agroaceite is the fourth company in the world, the third in Latin America, and the first in Central America to obtain the RSPO Next certification, which includes several advanced criteria that exceed the RSPO standard.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191120005702/en/
Contact information
Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
(502) 2420-9600
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom